Executive and scientist discuss operations in a modern pharmaceutical manufacturing facility.
Sun Pharma, the pharmaceutical giant helmed by Dilip Shanghvi, is reportedly on the verge of its most significant international acquisition to date, with a $12.5 billion deal in the works for Organon & Co. This move underscores Shanghvi’s consistent strategy of leveraging acquisitions to drive growth and expand the company’s global footprint.
Shanghvi, who began his journey as a small trader in Kolkata, has built Sun Pharma into a global powerhouse through a series of strategic buyouts. His approach has consistently focused on identifying companies with strong strategic advantages and turnaround potential. This philosophy has been instrumental in landmark deals in the past, including the acquisitions of Ranbaxy and Taro, which significantly bolstered Sun Pharma’s market position and capabilities.
The potential acquisition of Organon & Co. represents a continuation of this proven formula. By acquiring established entities, Sun Pharma aims to accelerate its expansion into new markets and enhance its product portfolio, reinforcing its status as a formidable player in the global pharmaceutical landscape. The success of this deal would further cement Shanghvi’s reputation as a shrewd “buyout artist” in the corporate world.
About the Author
